Aclaris Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 27, 2026, 5:25 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedAclaris Therapeutics Prices Underwritten Offering of 7,785,714 Shares and Pre-Funded Warrants for Approximately $46.7 Million Net Proceeds at $3.50 per Share
8-KOct. 27, 2026, 6:06 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedAclaris Therapeutics reports positive Phase 1b ATI-052 proof-of-concept data in atopic dermatitis and asthma, with cash of approximately $204.6 million as of September 30, 2026
8-KAug. 6, 2026, 5:15 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
8-KAug. 6, 2026, 7:15 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits